ArticleHepatology (Baltimore, Md.)2013
A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care.
Article in Hepatology (Baltimore, Md.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C.Addiction science & clinical practice · 2015Pooled it
- Nurse case management to improve the hepatitis C care continuum in HIV co-infection: Results of a randomized controlled trial.Journal of viral hepatitis · 2020Trial
- Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials.PloS one · 2016Trial
- Understanding Barriers to Hepatitis C Antiviral Treatment in Low-Middle-Income Countries.Healthcare (Basel, Switzerland) · 2024Review
- Risk of Hepatitis C Virus Infection in Tuberculosis Patients: A Systematic Review and Meta-Analysis.Iranian journal of public health · 2024Review
- Challenges and best practices for hepatitis C care among people who inject drugs in resource limited settings: focus group discussions with healthcare providers in Kenya.Global public health · 2022Article
- Sharing the cure: Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland.Journal of viral hepatitis · 2020Article
- Management of Hepatitis B Surface Antigen and Hepatitis C Antibody-Positive Patients by Departments Not Specializing in Hepatology at a Suburban University Hospital in Japan: A Single-Center Observational Study.International journal of general medicine · 2020Article
- [Proper patient education improves hepatitis C patients' disease-related knowledge and antiviral treatment acceptance in rural China].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018Article
- Awareness and knowledge of hepatitis C among health care providers and the public: A scoping review.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2018Article
- Addressing hepatitis C in the foreign-born population: A key to hepatitis C virus elimination in Canada.Canadian liver journal · 2018Review
- Patient Education Improves Patient Knowledge and Acceptance on Antiviral Therapy of Hepatitis C in Rural China.Chinese medical journal · 2017Article
- Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs.The International journal on drug policy · 2017Article
- Observational
- Hepatitis C among blood donors: cascade of care and predictors of loss to follow-up.Revista de saude publica · 2017Article
- The Rate of Referral of Hepatitis Virus Carriers to Hepatologists and the Factors Contributing to Referral.Internal medicine (Tokyo, Japan) · 2017Article
- Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar.PloS one · 2017Article
- Article
- Going Viral: Why Eliminating the Burden of Hepatitis C Requires Enhanced Cooperation Between Specialists and Primary Care Providers.Digestive diseases and sciences · 2016Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 12 institutions in 8 countries.
Funding
Abstract
unlabelledChronic infection with the hepatitis C virus (HCV) is a leading cause of global morbidity and mortality. Although recent advances in antiviral therapy have led to significant improvements in treatment response rates, only a minority of infected patients are treated. Multiple barriers may impede the delivery of HCV therapy. The aim of this study was to identify perceived barriers to care, knowledge, and opinions among a global sample of HCV treatment providers. An international, multidisciplinary survey of HCV treatment providers was conducted. Each physician responded to a series of 214 questions concerning his or her practice characteristics, opinions regarding the state of HCV care, knowledge regarding HCV treatment, and perception of treatment barriers. A total of 697 physicians from 29 countries completed the survey. Overall, physicians viewed patient-level barriers as most significant, including fear of side effects and concerns regarding treatment duration and cost. There were distinct regional variations, with Central and Eastern European physicians citing government barriers as most important. In Latin America, the Middle East, and Africa, payer-level barriers, including lack of treatment coverage, were prominent. Overall, the perception of barriers was strongly associated with physician knowledge, experience, and region of origin, with the fewest barriers reported by Nordic physicians and the most reported by Middle Eastern and African physicians. Globally, physicians demonstrated deficits in basic treatment principles, including the role of viral kinetics and the management of treatment nonresponders. Two thirds of surveyed physicians believed that patients do not have adequate access to providers in their community.
conclusionBarriers to HCV treatment vary globally, though patient-level factors are viewed as most significant by treating physicians. Efforts to improve awareness, education, and specialist availability are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.